Strategies for Supporting Patient Engagement and Decision Making
- Use of effective patient education and discussions during clinical interactions
- Understanding of how patient preferences and goals can affect treatment decisions for adjuvant therapy
- Discussion of specific steps for implementation into practice
Interactive Case Discussions: Adjuvant Treatment Options for HER2-Positive Early-Stage Breast Cancer
Patient case examples will be used to highlight current clinical data and application of nursing considerations for patients with HER2-positive early-stage breast cancer.
- Discussion of different case scenarios to guide discussions on adjuvant therapy
- How patient age, tumor/disease characteristics, preferences, and goals affect treatment considerations
- Identifying patients in which dual HER2 inhibition and/or extended duration of HER2 inhibition is reasonable
- Discussion of case scenarios for managing adverse events associated with adjuvant therapy
- Incidence and etiology of diarrhea and other symptoms associated with new adjuvant treatment options
- Dosing considerations and loperamide prophylaxis
Audience Question and Answer Session
Date / Time
Joyce A. O'Shaughnessy, MD
Celebrating Women Chair in Breast Cancer Research
Director, Breast Cancer Research Program
Baylor University Medical Center
US Oncology Network
The goal of this activity is to improve oncology nurses’ ability to educate, partner in shared decision making with, and optimally care for patients with HER2-positive early breast cancer.
This program is intended for oncology nurses and other healthcare providers who care for patients with HER2-positive early breast cancer.
- Support patient engagement and decision making through education and communication
- Explain to patients with HER2-positive early breast cancer how adjuvant therapy can be individualized, considering the available clinical evidence, expert recommendations, and their goals and preferences
- Identify subsets of patients most likely to benefit from adjuvant therapy with dual HER2 inhibition and/or extended adjuvant therapy with neratinib
- Discuss the benefits and risks of intensifying and/or extending adjuvant therapy with patients with HER2-positive early breast cancer
- Manage treatment-related symptoms experienced by patients with HER2-positive early breast cancer
Nursing Continuing Education
Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Clinical Care Options, LLC. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Provider approved by the California Board of Registered Nursing, Provider Number 13485, for 1.0 contact hour.
A statement of credit will be made available immediately upon completion of the online evaluation.
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hours.
Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. The existence or absence of COI for everyone in a position to control content will be disclosed to participants prior to the start of each activity.